Research programme: cannabinoid therapeutics - Aphios/VivaCell

Drug Profile

Research programme: cannabinoid therapeutics - Aphios/VivaCell

Alternative Names: APH-1305; APH-1403; Neurodegenerative disease therapeutics - Aphios Corporation/VivaCell Biotechnology Espana; VCE-003; VCE-003.1; VCE-003.2; VCE-004; VCE-004.8; Δ9 Tetrahydrocannabinoid; Δ9 THCA

Latest Information Update: 30 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aphios Corporation; Universidad Nacional de Cordoba; VivaCell Biotechnology Espana
  • Developer Aphios Corporation; Emerald Health Botanicals; Universidad Nacional de Cordoba; VivaCell Biotechnology Espana
  • Class Cannabinoids; Quinones
  • Mechanism of Action Cannabinoid receptor CB2 agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Fibrosis; Huntington's disease; Multiple sclerosis; Parkinson's disease; Scleroderma

Most Recent Events

  • 30 Sep 2016 Preclinical development is ongoing for Multiple sclerosis in USA and Spain (VivaCell Biotechnology and Aphios pipelines, September 2016)
  • 30 Sep 2016 Preclinical trials in Amyotrophic lateral sclerosis in Spain (PO)
  • 30 Sep 2016 Preclinical trials in Fibrosis in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top